CAR-T– tag –
-
CAR-T’s Geography Problem: Manufacturing Bottlenecks Limit Access, Advances in Closed Systems and Bioprocessing are Key
pharmaphorum UK Overview CAR-T cell therapy's geographical accessibility is heavily dependent on its manufacturing process, with production costs, turnaround times, and available facilities directly impacting patient access. A critical b... -
Closed-System Semi-Automated Manufacturing Key to Expanding CAR-T Access in Low- and Middle-Income Countries by Reducing Cost and Complexity
PubMed International Overview CAR-T cell therapy adoption in low- and middle-income countries (LMICs) has been severely constrained by high costs, insufficient infrastructure, and complex regulatory demands. However, the advent of closed... -
ProBio’s AAV Manufacturing Excellence Accelerates UC Irvine and GlyTR Therapeutics’ Pan-Cancer CAR-T Program, Achieving 80% CAR Gene Insertion Efficiency
University of California, Irvine USA Overview ProBio's advanced AAV manufacturing technology is critically powering pre-IND research for the first-in-class pan-cancer CAR-T program developed by UC Irvine and GlyTR Therapeutics. ProBio's ... -
Academic Point-of-Care Manufacturing Offers Cost-Effective CAR-T Access in Low- and Middle-Income Countries
PubMed Global Overview CAR-T cell therapy implementation in Low- and Middle-Income Countries (LMICs) faces significant hurdles due to insufficient infrastructure, complex regulations, and high costs. However, this review suggests that ad... -
MaxCyte & VectorBuilder Partner on Virus-Free Gene Delivery Platform for Ex Vivo Cell Therapies, Boosting CAR T-Cell Manufacturability
BioProcess International USA Overview CDMO VectorBuilder and MaxCyte have partnered to develop a virus-free gene delivery platform for ex vivo cell therapies, including CAR T cells. This collaboration integrates VectorBuilder's 'MiniVec'... -
Market Report: US Autologous CAR-T Cell Therapy Process Optimization Market Driven by Efficiency & Cost Reduction Needs
Intel Market Research USA Overview This article summarizes the "United States Autologous CART Cell Therapy Process Optimization Market Outlook 2026-2034" report. The US autologous CAR-T cell therapy process optimization market is driven ... -
CDMO Signal Ranks Top FDA & GMP-Compliant Lentiviral Vector Manufacturing CDMOs
CDMO Signal Global Overview CDMO Signal has released a ranking of top Lentiviral Vector (LVV) CDMOs, crucial for ex vivo gene therapy, based on FDA inspection history, GMP certification, clinical program activity, and capacity. LVVs are ... -
PackGene Biotech Accelerates Next-Gen CAR-T Development with Lentiviral and mRNA Technologies
PackGene Biotech China Overview PackGene Biotech is advancing next-generation CAR-T cell development by offering both lentiviral vector (LVV) and mRNA technologies for manufacturing. LVVs are a core technology enabling stable, long-term ... -
Gene-Edited iPSC-Derived CAR-T/NK Therapies Target Allogeneic Rejection for Off-the-Shelf Cancer Immunotherapy
MDPI Switzerland Overview Allogeneic T cell therapies represent a scalable, off-the-shelf alternative to autologous approaches, promising to overcome significant logistical and manufacturing limitations. The review highlights iPSC-derive... -
European Biotechs Unveil Next-Gen CGT Manufacturing to Cut CAR-T Costs Above €60,000 Per Patient
PharmTech Global Overview European biopharmaceutical companies are spearheading the development of advanced manufacturing technologies to address the high costs and logistical hurdles of Cell and Gene Therapies (CGT). Innovations include...
